Sign in Subscribe
Class action lawsuits

Securities Lawsuit Filed Against Hims & Hers Health, Inc. and Senior Executives

Strategic Insights

— 2 min read

A securities lawsuit has been filed against Hims & Hers Health, Inc. and certain of its senior executives for potential violations of federal securities laws. The lawsuit, captioned Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315, was filed in the U.S. District Court for the Northern District of California and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The complaint alleges that Hims & Hers misrepresented the nature of its partnership with Novo Nordisk and sold compounded semaglutide, a drug that can pose serious health risks, to its customers.

Key Takeaways:

  • The lawsuit was filed in the U.S. District Court for the Northern District of California (Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315).
  • Hims & Hers allegedly misrepresented the terms of its partnership with Novo Nordisk, including claiming it could offer compounded semaglutide to its customers.
  • The Novo Nordisk partnership was terminated due to Hims & Hers's "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk."
  • As a result, Hims & Hers's stock price fell by 34% on June 23, 2025, from $64.22 per share on June 20, 2025, to $41.98 per share.
  • The lawsuit seeks to represent investors who purchased Hims & Hers securities and alleges that the company engaged in deceptive practices.
  • Hims & Hers investors may have legal options and are encouraged to submit their information to Rosen Law Firm for potential participation in the case.
  • Bleichmar Fonti & Auld LLP, a leading international law firm representing plaintiffs in securities class actions and shareholder litigation, is also involved in the lawsuit.
  • The firm has been named a top plaintiff law firm by various publications and has recovered significant amounts for its clients in recent cases.

Statistics:

  • The lawsuit was filed in July 2025 (no specific date mentioned).
  • Investors have until August 25, 2025, to ask the Court to be appointed as lead plaintiff in the case.
  • Hims & Hers's stock price fell by $22.24 per share (34% of its value) on June 23, 2025.
  • The lawsuit seeks to represent investors who purchased Hims & Hers securities.
  • The firm will seek court approval for any potential fees and expenses.

Sources:

  • GlobeNewswire
  • U.S. District Court for the Northern District of California (Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315)
  • Novo Nordisk
  • Bleichmar Fonti & Auld LLP
  • Rosen Law Firm

Read more